<DOC>
	<DOCNO>NCT01415427</DOCNO>
	<brief_summary>This Phase 3 extension study evaluate long-term efficacy safety BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every week patient mucopolysaccharidosis IVA ( Morquio A Syndrome ) .</brief_summary>
	<brief_title>Long-Term Efficacy Safety Extension Study BMN 110 Patients With Mucopolysaccharidosis IVA ( Morquio A Syndrome )</brief_title>
	<detailed_description>This multi-center , multinational , extension study evaluate 2 dose regimen BMN 110 treatment patient MPS IVA complete MOR-004 . The last study visit assessment MOR-004 constitute Baseline study . The first study drug dose protocol occur Week 0 MOR-005 , last visit ( Week 24 ) MOR-004 . Initially , study double-blind patient previously randomize BMN 110 MOR-004 remain assign BMN 110 dose regimen ( qw qow dose ) . The MOR-004 placebo patient re-randomized ( 1:1 ratio ) one 2 BMN 110 dose regimen group : 2.0 mg/kg/qw 2.0 mg/kg/qow . There two study part : - Part 1 - randomize double-blind optimal BMN 110 dose regimen determine , base final primary efficacy analysis MOR-004 - Part 2 - open-label BMN 110 treatment single optimal dose regimen</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<criteria>Must complete MOR004 Is willing able provide write , sign informed consent . Or case patient age 18 ( age define regional law regulation ) , provide write assent ( require ) write informed consent , sign legally authorize representative , nature study explain , prior performance researchrelated procedure . If sexually active , must willing use acceptable method contraception participate study . If female , childbearing potential , must negative pregnancy test Baseline willing additional pregnancy test do study . Is pregnant breastfeeding , Baseline , plan become pregnant ( self partner ) time study . Has use investigational product ( BMN 110 MOR004 ) , investigational medical device , within 30 day prior Baseline ; require use investigational agent prior completion schedule study assessment . Was enrol previous BMN 110 study , MOR004 . Has concurrent disease condition , include limited , symptomatic cervical spine instability , clinically significant spinal cord compression , severe cardiac disease would interfere study participation , pose safety risk , determine Investigator . Has condition , view Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mucopolysaccharidosis IV type A</keyword>
	<keyword>MPS IV Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
</DOC>